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A quantitative structure–activity relationship (QSAR) study was carried out on 112 anticancer
compounds to develop a robust model for the prediction of anti-leukemia activity (pGI50)
against MOLT-4 and P388 leukemia cell lines. The Genetic algorithm (GA) and multiple linear
regression analysis (MLRA) were used to select the descriptors and to generate the correlation
models that relate the structural features to the biological activities. The ﬁnal equations consist
of 15 and 10 molecular descriptors calculated using the paDEL molecular descriptor software.
The GA-MLRA analysis showed that the Conventional bond order ID number of order 1
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NCI database(piPC1), number of atomic composition (nAtomic), and Largest absolute eigenvalue of Burden
modiﬁed matrix – n 7/weighted by relative mass (SpMax7_Bhm) play a signiﬁcant role in pre-
dicting the anticancer activities of these compounds. The best QSAR model for MOLT-4 was
obtained with R2 value of 0.902, Q2LOO = 0.881 and R
2
pred = 0.635, while for P388 cell line
R2 = 0.904, Q2LOO = 0.856 and R
2
pred = 0.670. The Y-scrambling/randomization validation also
conﬁrms the statistical signiﬁcance of the models. These models are expected to be useful for pre-
dicting the inhibitory activity (pGI50) against MOLT-4 and P388 leukemia cell lines.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1 The predicted pGI50 against the experimental values for
the training and test sets of P388 leukemia cell line.Introduction
Leukemia is a word that is attributed to cancer of the blood
cells, which creates uncontrollable quantities of irregular white
blood cells in the blood and bone marrow, swarming out ordi-
nary blood cells. The low level of ordinary blood cells makes it
difﬁcult for the body to get oxygen to its tissues, battle diseases
and control bleeding [1]. QSAR models in modern time are
important tool for predicting the inhibition of such aliments
via chemotherapeutic means [2]. There are four regular sorts
of leukemia the vast majority of which are gathered in view
of how rapidly the sickness deteriorates (chronic) and on the
platelet the disease begins in (lymphoblastic or myeloid) [3].
Human leukemia is one of the generally analyzed neoplasms.
Most leukemia cell lines gain resistance to the different systems
that prompt the human cell demise [4]. Melphalan is a
chemotherapy medication ﬁtting in with the class of nitrogen
mustard alkylating operators, which moderates the develop-
ment of growth cells in anyone [5], yet it has been found to
be inadequate, and hence these outcomes set the path in the
consistent interest and quest for a more successful nontoxic
leukemia cell inhibitor [4].
Quantitative structure–activity relationship (QSAR) study
performs an urgent part in novel drug design and conﬁgura-
tion via a ligand-based approach [6]. Such methodologies are
unequivocally judgmental to give not just the solid forecast
of particular properties of new analogs, but also illustrate
the conceivable molecular mechanism of the receptor–ligand
interaction [7]. Quantitative structure–activity relationship
(QSAR) [8], has been generally utilized for a long time to give
quantitative investigation of structure and biological activity
relationships of compounds [9,10]. The importance of QSAR
application in pharmaceutical industry and risk assessment
cannot be over emphasized as review of its growing applica-
tions in these areas was reported by Roy et al. [11].
As of late 2015, computer assisted drug design based on
QSAR has been effectively utilized to develop new medications
for the treatment of cancer [8,12–14], AIDS, SARS, and other
ailments. Selassie et al. [15] analyzed the cytotoxicity of com-
plex mono-substituted phenols toward a fast-developing mur-
ine leukemia cell line (L1210). Despite the fact that the interest
for ‘‘in silico” revelation is clear in every aspect of human ther-
apeutics, the ﬁeld of anti-infective medications has a speciﬁc
requirement for computational treatment empowering quick
distinguishing proof of novel therapeutic leads [16]. The
multidrug-resistance (MDR) of tumor cells to chemotherapeu-
tic operators is a noteworthy issue in the clinical treatment of
malignancy [17]. It is the capacity of cancer cells exposed to
chemotherapeutics to resist a wide scope of medications [18].The inability of anticancer drugs to mitigate cancer in some
cancer cell lines and their accompanying side effects build the
quest for novel treatment choices of this illness [8,19]. Goyal
and his colleagues showed that curcumin which destroys a
few tumor cell lines can as well suppress the immune system
[20].
In this work, the activity of anti-leukemia compounds col-
lected from NCI database (Fig. 1) against P388 and MOLT-4
leukemia cell lines was modeled using several statistical tools,
including genetic functional algorithm for variable selection,
multiple linear regression (MLR) for modeling and Euclidean
based applicability domain for outlier detection.
Material and methods
Experimental dataset
In this study, a dataset of 112 compounds was used to model
the relationship between the chemical ﬁngerprints of the com-
pounds and their anticancer activities on human acute lym-
phoblastic leukemia (MOLT-4) and multidrug-resistant P388
leukemia cell line. The chemical structures of the dataset,
NSC and CAS number were taken from the drug discovery
and development arm of the National Cancer Institute
(NCI). Eligible compounds were determined by reviewing
and curating the raw data collected from the literature (NCI
QSAR study of some compounds against MOLT-4 and P388 leukemia cell lines 825database), which is openly available to the general public on
the DTP Web site (http://dtp.cancer.gov/mtargets/mt_index.
html), while the anticancer screening method and assay used
to measure the biological activities are reported in the DTP-
NCI Web site (http://dtp.nci.nih.gov/branches/btb/ivclsp.
html). The data contain aminopterin and camptothecin deriva-
tives, colchicine analogs and so on. The anticancer activity
results are expressed as GI50, which is the concentration for
50% of maximal inhibition of cancer cell proliferation.
The biological activity (LogGI50) of the studied com-
pounds was presented in Table 1 and the dataset of the activ-
ities differs from 3.1 to 9.1 (M) for MOLT-4 and 3.1 to 9.2 (M)
for P388. Further literature [21], claims that GI50 around
5 mM is considered reasonably active while 10 mM proposes
that a compound is inactive. Since the grouping proposed in
this study incorporates two conceivable outcomes, active and
inactive, it was agreed that a limit estimation of 10 mM would
best incorporate more different chemical structures giving
helpful data to further understand the activity of the
compounds.
Geometry optimization and molecular descriptor calculation
The 2D structures of the compounds presented in the Supple-
mentary Table were drawn utilizing chemdraw programming
[22] and these structures afﬁrmed with the mol document
recovered from ChemicalBook search engine (http://
www.chemicalbook.com/) through their individual CAS num-
ber. The spatial conformations of the compounds were
resolved through the Spartan 14 V1.1.4 WaveFunction pro-
gramming package. The chemical structures were initially min-
imized by Molecular Mechanics Force Field (MM+) count to
remove strain energy before subjecting it to quantum chemical
estimations. Further computation includes DFT (density func-
tional theory) method for complete geometric optimization of
the structures.
These methods have turned out to be extremely well known
lately in light of the fact that they can reach comparable accu-
racy to empirical methods in less time and less cost from the
computational perspective. In concurrence with the DFT
results, energy of the standard condition of a polyelectronic
framework can be elaborated through the aggregate electronic
density. It is imperative to note that the utilization of electronic
density rather than wave capacity for ascertaining the energy,
constitutes the base of DFT [23], utilizing the B3LYP hybrid
functional [24,25] and a 6-311G* basis set.
The B3LYP hybrid functional of DFT method, uses
Becke’s three-parameter functional (B3) and incorporates a
blend of HF with DFT exchange terms associated with the gra-
dient corrected correlation functional of Lee, Yang and Parr
(LYP). The geometry of all species under scrutiny was con-
trolled by upgrading every single geometrical variable with
no symmetry constraints. The Spartan ﬁles of all the optimized
molecules were then saved in SD ﬁle format, which is the rec-
ommended input format in PaDEL-Descriptor software V2.20
[26].
1875 (1444 1D, 2D descriptors and 431 3D descriptors)
molecular descriptors such as atom-type electrotopological
state descriptors, 2D-Autocorrelations, WHIM, Petitjean
shape index, count of chemical substructures identiﬁed by
Laggner, and binary ﬁngerprints of chemical substructuresidentiﬁed by Klekota and Rothk [27], were calculated using
the paDEL program (PaDEL-Descriptor, 2014). In addition
to the PaDEL descriptors, a few other descriptors were incor-
porated into the analysis. These 5 descriptors (molecular
dipole moment, total energy, energy of the HOMO and
LUMO molecular orbitals, and HOMO–LUMO gap) were
obtained from the DFT computation.
Data normalization
The calculated molecular descriptors were standardized by a
technique preserve range (maximum and minimum) before
they were transformed into a N(0,1) dispersion, making the
correlation between descriptors (probabilities computation)
much less demanding [28].
Variable selection
Selecting the most pertinent descriptors for QSAR examina-
tion is one of the vital strides, subsequent to the development
of a model. Genetic algorithm was used to select the most sig-
niﬁcant descriptors with respect to an objective function [29–
31]. Genetic algorithm system was initially created by Leardi
et al. in 1992 [32] and the ﬁrst step in performing Genetic algo-
rithm is the generation of vast number of haphazardly chosen
variables, in QSAR studies and these variables incorporated
into every model are molecular descriptor [33].
These selected subsets of variables are further assessed for
their ability to predict their biological activities through the
use of cross-validation correlation coefﬁcient of leave-one-
out (Q2LOO derived based on MLR) [32]. Genetic algorithm sys-
tem as a selection tool was incorporated into Material studio 7
program (Accelrys Material Studio, 2014) and utilized here.
The Genetic algorithm method (GA) begins with the forma-
tion of a populace of randomly produced parameter sets.
The probability of a given parameter from the active set is
0.5 in any of the initial population sets. The parameter set used
for the GA incorporates the boundaries for mutation (0.1),
hybrid (0.9), population (10,000), number of model generation
(1000), R2 ﬂoor limit (50%), and target capacity (R2/N_par).
The making of a successive generation includes crossovers
between set substances and additionally changes. The calcula-
tion keeps running until the wanted number of generations is
achieved. Equations were generated between the experimental
biological activity and the descriptors. The best mathematical
statement was taken in light of statistical parameters such as
squared regression coefﬁcient (R2) and leave-one-out cross-
validated regression coefﬁcient (Qcv
2 ).
Data division
In order to obtain validated QSAR models the dataset was
divided into training and test sets. Ideally, this division should
be performed such that points representing both training (80%
of compounds) and test sets (20% of compounds) are dis-
tributed within the whole descriptor space occupied by the
entire dataset, and each point of the test set is close to at least
one point of the training set. This partitioning ensures that a
similar principle can be employed for the activity prediction
of the test set. Kennard–Stone Algorithm will be applied for
dividing Dataset into a Training and Test set [34].
Table 1 Chemical names of dataset with NSC numbers and targeted cell lines.
Serial
number (ID)
Name NSC MOLT-4
(experimental pGI50)
MOLT-4
(predicted pGI50)
P388
(experimental pGI50)
P388
(predicted pGI50)
1 11-formyl-20(RS)-camptothecin 606,172 6.9 6.55 – –
2 11-hydroxymethyl-20(RS)-camptothecin 606,173 5.4 5.25 – –
3 14-chloro-20(S)-camptothecin hydrate 643,833 6.5 7.43 – –
4 20-deoxy-5-ﬂuorouridine 27,640 6.4 5.89 6.6 6.04
5 3-HP 95,678 6 5.49 6.5 6.31
6 5,6-dihydro-5-azacytidine 264,880 5.4 5.86 5.1 5.34
7 5-AZA-20-deoxycytidine 127,716 4.2 5.19a 7.3 6.23
8 5-azacytidine 102,816 5.6 6.06 6.3 6.57
9 5-HP 107,392 5.6 5.78 5.7 6.39
10 7-chlorocamptothecin 249,910 8 7.44 – –
11 9-amino-20-(R,S)-camptothecin 629,971 6 6.93 – –
12 acivicin 163,501 5.6 5.46a 6.6 6.28
13 allocolchicine 406,042 8 8.31a – –
14 alpha-TGDR 71,851 4.2 4.69 4.5 5.62
15 Aminopterin derivative1 132,483 6.3 8.73a 7.5 7.71
16 Aminopterin derivative2 184,692 7.6 7.79 7.8 7.76
17 Aminopterin derivative3 134,033 7.6 7.75 8 7.46
18 Amonaﬁde 308,847 6 5.70 6.3 5.83
19 An antifol 623,017 7.7 7.73 8 9.49b,*
20 Anthrapyrazole derivative 355,644 7.8 7.30 7.8 7.25
21 Aphidicolin glycinate 303,812 5.7 5.65 – –
22 ARA-C 63,878 7.3 6.45 7.3 6.22b
23 Asaley 167,780 6.5 7.28a 5.8 7.45b
24 AZQ 182,986 5.9 5.81 5.8 6.23
25 Baker’s soluble antifol 139,105 6.9 6.91 7 6.59
26 BCNU 409,962 4.5 4.29 5.2 3.81b
27 BETA-TGDR 71,261 6.2 5.01 6.5 6.02
28 Bisantrene HCL 337,766 7.4 5.93a 7.5 7.39
29 Brequinar 368,390 7 7.04a 6.4 5.98
30 Busulfan 750 3.9 4.69 3.9 4.01
31 Camptothecin 94,600 6 6.81 7.6 7.79b
32 Camptothecin analog 295,500 7.8 6.97 – –
33 Camptothecin analog2 606,985 8 8.49a – –
34 Camptothecin analog3 295,501 8 8.11 – –
35 Camptothecin butylglycinate ester hydrochloride 606,499 7.9 8.58 – –
36 Camptothecin ethylglycinate ester hydrochloride 606,497 7.7 8.03 – –
37 Camptothecin glutamate HCL 610,459 8 8.20 – –
38 Camptothecin hemisuccinate sodium salt 610,456 8 7.47 – –
39 Camptothecin lysinate HCL 610,457 8 7.95a – –
40 Camptothecin phosphate 610,458 8 8.05 – –
41 Camptothecin, 9-methoxy- 176,323 7.8 7.61a – –
42 Camptothecin, acetate 95,382 6.6 7.99a – –
43 Camptothecin, hydroxy- 107,124 8 7.45a 7.6 7.78
44 Camptothecin, NA salt 100,880 7.6 7.04 7.6 7.59
45 Camptothecin,20-O-((4-(2-hydroxyethyl)-1-piperazino)OAC 374,028 7.4 7.02a – –
46 Camptothecin-20-O-(N,N-dimethyl)glycinate HCL 618,939 8.6 8.65a – –
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47 CCNU 79,037 4.7 4.48 5.4 5.69
48 Chlorambucil 3088 5.1 5.11 5.4 5.67
49 Chlorozotocin 178,248 3.6 3.94 4 5.20b
50 Clomesone 338,947 3.9 1.51a,* 4.7 4.11
51 Colchicine 757 7.2 7.51 7.2 7.51
52 Colchicine derivative 33,410 6.7 6.62a – –
53 Cyanomorpholinodoxorubicin 357,704 8.6 8.42 8.6 7.90
54 Cyclocytidine 145,668 6.5 6.55a 7 6.27b
55 Cyclodisone 348,948 4.8 5.00 5 4.71
56 Daunorubicin 82,151 7.1 7.30 7.1 7.66b
57 Deoxydoxorubicin 267,469 7.4 7.46 7.5 7.73
58 Dianhydrogalactitol 132,313 5.2 5.38 4.9 4.95
59 Dichlorallyl lawsone 126,771 5.8 5.02 5.7 5.77
60 Dolastatin 10 376,128 9.6 9.24 – –
61 Doxorubicin 123,127 7.9 7.81 – –
62 Fluorodopan 73,754 4.2 6.26a 3.9 3.66b
63 Ftorafur (pro-drug) 148,958 3.1 3.83 4.6 5.17
64 Glycinate 364,830 8 7.68 – –
65 Guanazole 1895 2.5 4.22a 3.1 3.31
66 Hepsulfam 329,680 4.5 4.07 4.5 4.54b
67 Hycanthone 142,982 5.3 5.60 5.5 5.97
68 Hydroxyurea 32,065 3.7 4.11 4.2 3.93
69 Inosine glycodialdehyde 118,994 3.9 4.37 4.1 3.92*
70 L-alanosine 153,353 4.7 5.59a 4.8 5.07
71 Macbecin II 330,500 7.1 8.78a,* – –
72 M-AMSA 249,992 7.4 6.81 7.6 7.25
73 Maytansine 153,858 7.8 7.43 8 8.38
74 Melphalan 8806 5.5 5.75 5.6 5.73
75 Menogaril 269,148 7.5 7.71 7.3 7.69
76 Methotrexate 740 7.4 7.41 7.6 8.73b,*
77 Methotrexate derivative 174,121 8.2 8.21 – –
78 Methyl CCNU 95,441 4.7 4.65 5.8 5.72
79 Mitomycin C 26,980 6.5 6.95 6.7 6.33
80 Mitoxantrone 301,739 8.3 8.38 8.4 8.23
81 Mitozolamide 353,451 4.5 4.65 4.9 5.15
82 Morpholinodoxorubicin 354,646 8.6 8.90 8.6 8.13b
83 N-(phosphonoacetyl)-L-Aspartate (PALA) 224,131 3.7 4.09 3.9 3.85b
84 N,N-dibenzyl daunomycin 268,242 5.2 5.17 6.2 6.40*
85 Nitrogen mustard 762 6.5 6.37 7.3 7.37*
86 Oxanthrazole 349,174 6.6 7.19 6.8 7.47b
87 PCNU 95,466 4.3 4.59 4.8 5.06
88 Piperazine drugsmainator 344,007 5.1 4.62 4.8 4.95
89 Piperazinedione 135,758 7 6.77 6.6 6.30
90 Pipobroman 25,154 4.8 4.92 4.9 5.13
91 Porﬁromycin 56,410 6.1 5.96 5.7 6.41
92 Pyrazofurin 143,095 6.2 6.16 6.3 5.98
93 Pyrazoloacridine 366,140 6.9 6.86 6.8 7.26
94 Pyrazoloimidazole 51,143 3.3 3.33 3.4 3.49
95 Rhizoxin 332,598 8 7.92 8 7.94*
(continued on next page)
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828 D.E. Arthur et al.Objective function¼
XKþ1
i¼1
f½lðiÞtrainlðiÞtestþ½rðiÞtrainrðiÞtestg
K is the number of inputs, while l and r are mean and stan-
dard deviation of the input or output variable, respectively.
With this technique, all objects are considered as candidates
for the training set. The selected candidates are chosen
sequentially.
KS algorithm can be summarized as follows: First, the KS
algorithm takes the pair of samples with the largest Euclidean
distance ofx-vectors (predictors), and then it sequentially selects
a sample to maximize the Euclidean distance between x-vectors
of already selected samples and the remaining samples. This pro-
cess is repeated until the required number of samples is achieved.
The algorithm employs Euclidean distance EDx (pq), between
the x vectors of each pair (p,q) of samples to ensure a uniform
distribution of such a subset along the x data space
EDxðp; qÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXN
j¼1½xpðjÞ  xqðjÞ2
r
p; q 2 ½1;M
N is the number variables in x andM is the number of samples,
while xp (j) and xq (j) are the jth variable for samples p and q,
respectively.
Model development
MLR is a strategy, utilized for displaying direct relationship
between a dependent variable Y (pGI50) and independent vari-
able X (atomic descriptors). The model is ﬁt such that sum-of-
square difference between the experimental and predicted val-
ues of set biological activity is minimized. In regression analy-
sis, contingent mean of dependant variable (pGI50) Y relies on
(descriptors) X. MLR examination extends this thought to
incorporate more than one autonomous variable, and regres-
sion equation takes the form.
Y ¼ b1x1 þ b2x2 þ b3x3
where Y is dependent variable, ‘b’s are regression coefﬁcients
for corresponding ‘x’s (independent variable), and ‘c’ is a
regression constant or intercept.
Evaluation of the QSAR model
The established QSAR models are judged by the statistical
measures: n (Number of compounds in regression); K (Number
of descriptors); DF (Degree of freedom); R2 (the squared cor-
relation coefﬁcient); F test (Fischer’s Value) for statistical sig-
niﬁcance; Q2 (cross-validated correlation coefﬁcient); pred R2
(R2 for external test set); Zscore (Z score calculated by the ran-
domization test); rand R2 (highest R2 value in the randomiza-
tion test); randQ
2 (highest Q2 value in the randomization test).
The regression coefﬁcient R2 evaluates the difference in the
experimental activities of the dataset calculated by the regres-
sion equation. Nonetheless, a QSAR model is thought to be
predictive, if the accompanying conditions are fulﬁlled:
R2 > 0.6, Q2 > 0.6 and pred R2 > 0.5. The F-test mirrors
the proportion of ﬂuctuation clariﬁed by the model and change
because of the error in the regression. High estimations of the
F-test show that model is statistically signiﬁcant. The low stan-
dard error of predR
2
se, Q
2
se and R
2
se demonstrates total nature of
the quality of the model.
QSAR study of some compounds against MOLT-4 and P388 leukemia cell lines 829Validation of the QSAR model
The capability of the QSAR equation to predict bioactivity of
new compounds was determined using the leave-one-out cross-
validation method. The cross-validation regression coefﬁcient
(Qcv
2 ) was calculated with the following equation:
Q2cv ¼ 1 PRESS=TOTAL ¼ 1
Pn
i¼1ðyexp  ypredÞ2Pn
i¼1ðyexp  yÞ2
where ypred, yexp, and ~y are the predicted, experimental, and
mean values of experimental activity, respectively. Also, the
accuracy of the prediction of the QSAR equation was vali-
dated by F-value, R2 and R2adj. A large F-value demonstrates
the possibility of a chance correlation in the model is mini-
mum. It has been reported that high estimation of statistical
attributes is not enough for the veriﬁcation of an exceedingly
prescient model [2]. Thus, to assess the predictive capacity of
the new QSAR model, the method depicted by Golbraikh
and Tropsha [2] and Roy et al. [11] was utilized. The
estimations of the correlation coefﬁcient and the coefﬁcient
of determination for regression models through the origin (pre-
dicted vs. actual activities) were calculated using the regression
analysis Tool-pack option in MS-Excel. The coefﬁcient of
determination for the test set Rtest
2 , was calculated through
the accompanying mathematical statement
R2Test ¼ 1
P ðYpredtest  YTestÞ2P ðYpredtest  YTrainingÞ2
where Ypredtest and YTest are the predicted value founded on the
QSAR equation (model response) and experimental activity
values, respectively, of the external test set compounds.
YTraining is the average activity value of the training set com-
pounds [35]. Additional assessment of the predictive ability
of the QSAR model for the test set compounds was done by
determining the value of (r2m), using the rm
2 metric calculator
developed by Roy et al. [36]. The latest version reported in
his paper ‘‘Some case studies on application of r2m metrics for
judging quality of quantitative structure–activity relationship
predictions: Emphasis on scaling of response data” which
utilizes a scaled response data i.e. observed and predicted
activity results, was used in this case and the result reported
on a table.
The values of k and k0 [2], slopes of the regression line of the
predicted activity versus actual activity and vice versa, were
calculated using the following equations:
k ¼
P
yiyiP
y2i
and k0 ¼
P
yiyiP
y2i
yi and yi are the predicted and experimental activities,
respectively.
Further statistical inference of the relationship between
activity and the descriptors was tested by randomization test
(Y-randomization) of the models. The Y column sections were
scrambled and new QSAR models were produced using the
same arrangement of variables as present in the unrandomized
model. The parameter Rp
2 penalizes the model R2 for the dif-
ference between squared mean correlation coefﬁcient (Rrand
2 ) of
randomized models and squared correlation coefﬁcient (R2) of
the nonrandomized model. The Rp
2 parameter was computed
by the accompanying mathematical statement:R2p ¼ R2 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
R2  R2rand
q
This parameter, R2p, guarantees that the models therefore
created are not obtained by luck. We have expected that the
estimation of R2p, ought to be more prominent than 0.5 for a
worthy model.
y-Randomization test
To guarantee the created QSAR model is strong and not
inferred by chance, the y-randomization test was performed
on the training set data as suggested by Tropsha et al. [35].
In this test, MLR models are created by randomly scrambling
the dependent variable (activity data) while keeping the inde-
pendent variable (descriptors) unaltered. The subsequent mod-
els are relied upon to have fundamentally low R2 and cross
validated Q2 values for a few trials, which afﬁrm that the cre-
ated models are good. 10-y-randomization tests were per-
formed, all but one of the models have the estimations of R2
and q2LOO > 0.5. This test afﬁrms that the created model is
powerful and not inferred by chance.
Degree of contribution of selected descriptors
The contribution of each descriptor in the model was quanti-
ﬁed by calculating their standardized regression coefﬁcients
(bsj ) through the accompanying mathematical statement:
bsj ¼
sjbj
sY
j ¼ 1; . . . ; d
where bsj is the regression coefﬁcient of descriptor j, and sj and
sY are the standard deviations for that descriptor and activity,
respectively. bsj statistical property allows one to assign a
greater importance to those molecular descriptors that exhibit
larger absolute standardized coefﬁcients.
Evaluation of the applicability domain of the model
Assessment of the applicability domain of the QSAR model is
viewed as an important step in establishing that the model is
equipped to make predictions within the chemical space for
which it was produced [35]. The leverage approach was utilized
in describing the applicability domain of the QSAR models
[37], Leverage of a given chemical compound hi, is deﬁned as
follows: hi ¼ xi ðXTXÞ1xTi ði ¼ 1; . . . ;mÞ, where xi is the
descriptor row-vector of the query compound i, and X is the
n k descriptor matrix of the training set compounds used
to develop the model. As a prediction tool, the warning lever-
age (h*) is the limit of normal values for X outliers and is
deﬁned as follows: h ¼ 3ðkþ 1Þ=n, where n is the number of
training compounds, and k is the number of descriptors in
the model. The test compounds with leverages hi < h
 are con-
sidered to be reliably predicted by the model. The Williams
plot, a plot of standardized residuals versus leverage values,
is utilized to translate the relevance area of the model in terms
of chemical space. The domain of unfailing prediction for
external test set molecules’ is deﬁned as compounds which
have leverage values within the threshold ðhi < hÞ and stan-
dardized residuals no greater than 3a (3 standard deviation
units), and hence they are accepted as Y outlier. Test set
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Fig. 2 The Residuals against the experimental pGI50 values for
the training and test sets of P388 leukemia cell line.
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Fig. 3 The predicted pGI50 against the experimental values for
the training and test sets of MOLT-4 leukemia cell line.
830 D.E. Arthur et al.compounds where ðhi > hÞ are thought to be unreliably antic-
ipated by the model because of considerable extrapolation. For
the training set, the Williams plot is utilized to recognize com-
pounds with the best structural inﬂuence ðhi > hÞ in develop-
ing the model
Results and discussion
A QSAR examination was performed to investigate the struc-
ture–activity relationship of 112 compounds with distinctive
organic moiety acting as anticancer. The nature of models
in a QSAR study is expressed by its ﬁtting and forecast
capacity.
QSAR on P388 and MOLT-4 cell line dataset
In order to assemble a decent QSAR model for the cytotoxicity
of P388 leukemia cell line with good predictive power for the
selected test set, a dataset of 85 compounds was divided into
a training set of 68 compounds used in developing the model
and a test set of 17 compounds, which was applied to assess
the predictive ability built model. The GA–MLR investigation
led to the selection of 10 descriptors, used to assemble a linear
model for calculating pGI50 activity on P388 cell line,
P388 cell line:
pGI50 ¼ 0:610ðnAmideÞ 4:599ðnMethanalÞþ 2:972ðS aaNÞ
þ 1:235ðAATSC4vÞþ 7:024ðSpMax7 BhmÞ
þ 2:099ðAVP-6Þþ 1:711ðmaxHdsCHÞ 3:440ðTDB8eÞ
þ 5:544ðRDF150uÞ 6:078ðRDF140vÞþ 1:852
Ntrain ¼ 68; R2train ¼ 0:904; R2adjusted ¼ 0:888;
Ftrain ¼ 53:899; Q2LOO ¼ 0:856; Outliers > 3:0 ¼ 0;
Ntest ¼ 22; R2test ¼ 0:670; RMSEtrain ¼ 0:423;
RMSEtest ¼ 1:02
The same technique was adopted for 112 compounds of
the second cell line MOLT-4, in which 90 compounds were
chosen for preparing and building up the model, while the
remaining 22 compounds were utilized as test set, and this
division in the ratio of 80–20 in information of both cell
lines, was accomplished by utilizing the Kennard–Stone
algorithm, as further outlined in the methodology aforesaid.
The GA-MLR model developed was validated internally and
externally and the model for MOLT-4 cytotoxicity was
found to constitute 15 molecular descriptors after obeying
Occam’s razor.
MOLT-4 cell line:
pGI50 ¼ 16:423ðAtomic compositionðtotalÞÞ
þ 2:914ðATSC8vÞ  1:457ðMATS2iÞ
 3:654ðVE2 DzZÞ  1:844ðnaasNÞ
 2:277ðminHBint3Þ  3:206ðminHBint10Þ
þ 1:037ðmaxHotherÞ þ 1:576ðnAtomLACÞ
 2:730ðMDEC 22Þ  21:680ðpiPC1Þ
þ 13:764ðTpiPCÞ  5:084ðRDF60uÞ  1:791ðKuÞ
þ 1:635ðL3mÞ þ 7:612Ntrain ¼ 90; R2train ¼ 0:920; R2adjusted ¼ 0:904;
Ftrain ¼ 56:982; Q2LOO ¼ 0:881; Outliers > 3:0 ¼ 0;
Ntest ¼ 22; R2test ¼ 0:635; RMSEtrain ¼ 0:416;
RMSEtest ¼ 1:160
N is the number of compounds, R2 is the squared correlation
coefﬁcient, Q2LOO, is the squared cross-validation coefﬁcients
for leave one out, F is the Fisher statistic, and RMSE is the
root mean square error.
The built model was used to predict the test set data, and
the results are presented in Table 1. The predicted pGI50 values
for the compounds in the training and test sets for P388 leuke-
mia cell line were plotted against the experimental pGI50 val-
ues in Fig. 1. Likewise, the plot of the residuals values for
both the training and test sets against the experimental
pGI50 estimations of P388 cell line is shown in Fig. 2, while
that for MOLT-4 cell line is plotted in Figs. 3 and 4,
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Fig. 4 The Residuals against the experimental pGI50 values for
the training and test sets of MOLT-4 leukemia cell line.
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Fig. 5 The Williams plot, the plot of the standardized residuals
versus the leverage value for MOLT-4 dataset.
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Fig. 6 The Williams plot, the plot of the standardized residuals
versus the leverage value for P388 dataset.
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computed values for the pGI50 are in great concurrence with
those of the test set, and hence the model did not demonstrate
any relative and systematic error, since the arrangement of the
residuals on both sides of zero is arbitrary.
QSAR analysis carried out on P388 (leukemia) cell line
using a dataset containing 39 (training set), 9 (test set) and 6
(predicted set), was reported by Davis and Vasanthi [8]. The
QSAR P388 model in this literature was reported to have an
R2 value of 0.72 and Q2CV value of 0.66, which pales in compar-
ison with the R2 and Q2CV (0.904 and 0.856) values of P388
reported in this paper.
QSAR model validation
The genuine value of QSARmodels is not only their capacity to
reproduce known activities of a compound, conﬁrmed by their
ﬁtting power (R2), but for the most part is their potential for
predicting biological activity. Therefore, the internal consis-
tency of the training set was conﬁrmed by using leave-one-out(LOO) cross-validation method to guarantee the strength of
the model. The high Q2LOO value for P388 and MOLT-4
(0.856 and 0.881) commends a decent internal validation.
The leverages for every compound in the dataset were plot-
ted against their standardized residuals, leading to discovery of
outliers and inﬂuential chemicals in the models. Fig. 5 shows
the Williams plot of MOLT-4 dataset. The applicability
domain is established inside a squared area within ±3 bound
for residuals and a leverage threshold h* (h ¼ 3po=n, where po
is the number of model parameters and n is the number of
compounds) [38,39]. From our result it is evident that all the
compounds of the training set and test set for MOLT-4 dataset
were within the square area, with exception of four compounds
having the ID number (50, 71, 98 and 106), which were not
within the applicability domain of the model. This was attrib-
uted to strong differences in their chemical structures com-
pared to the outstanding compounds in the dataset. In
addition, no outlier compounds with standardized residu-
als > 3d for the dataset were identiﬁed.
The Williams plot for the training set shown in Fig. 6,
establishes applicability domain of the model within ±3d
and a leverage threshold h* = 0.388 for P388 dataset. It can
be seen from Fig. 6 that ﬁve of the training set compounds
and two of the test set compounds were out of the applicability
domain of the model, and they were identiﬁed and could be
referred on Table 1 with their ID numbers (19, 69, 76, 84,
85, 95 and 109). All these compounds have their leverage val-
ues greater than the warning leverage (h*) value, and their high
leverages are responsible for swaying the performance of the
model, while the outstanding compounds were within the mar-
gin for the applicability domain of the model. However, all
their standard residual values are very low and within the
established limit. Therefore, the model can be applied with
conﬁdence within the deﬁned applicability domain.
To look at the relative signiﬁcance, and the contribution of
every descriptor in the model, for every descriptor the estima-
tion of the mean effect (MF) was ascertained. This was
achieved by using an MF mathematical statement which is
given as
832 D.E. Arthur et al.MFj ¼
bj
Pi¼n
i¼1dijPm
j bj
Pn
i dij
MFj represents the mean effect for the considered descriptor j,
bj is the coefﬁcient of the descriptor j, dij stands for the value of
the target descriptors for each molecule, and m is the descrip-
tor’s number in the model.
The MF value provides important information on the effect
of the molecular descriptors in the developed model, the signs
and the magnitude of these descriptors combined with their
mean effects reveals their individual strength and direction in
inﬂuencing the activity of a compound. The mean effect values
are presented in Tables 2.1 and 2.2 for MOLT-4 and P388
respectively, the degree of contribution bsj was calculated to
estimate a standardized regression coefﬁcients of the descrip-
tors used in the model, and their values in the case of P388
model were found to correlate with the mean effects (MF) of
its descriptors. SpMax7_Bhm contributes positively to the
activity of the anticancer compounds, and its contribution
along with that of TDB8e which is a 3D topological distance
descriptor was signiﬁcantly greater than other descriptors pre-
sent in the model. In the case of MOLT-4 model, three molec-
ular descriptors were signiﬁcantly high; they include piPC1 and
TpiPC conventional bond order descriptors having the mean
effects of 11.476 and 7.837 respectively, while nAtomicTable 2.1 Speciﬁcation of entered descriptors in genetic algorithm
Descriptors Deﬁnition Descriptor typ
nAtomic composition
(total)
Total number of atoms in the
molecule
Constitutional
ATSC8v centered:centred Broto-Moreau
autocorrelation of lag 8 weighted
by van der Waals volume
2D autocorrela
MATS2i Moran autocorrelation of lag 2
weighted by ionization potential
2D autocorrela
VE2_DzZ Average coeﬃcient of the last
eigenvector from Barysz matrix
weighted by atomic number
2D matrix-base
naasN Number of atoms of type aasN Atom-type E-s
minHBint3 Minimum E-State descriptors of
strength for potential Hydrogen
Bonds of path length 3
2D Atom type
minHBint10 Minimum E-State descriptors of
strength for potential Hydrogen
Bonds of path length 10
2D Atom type
maxHother Maximum atom-type H E-State:
H on aaCH, dCH2 or dsCH
2D Atom type
nAtomLAC Number of atoms in the longest
aliphatic chain
2D Longest Al
MDEC-22 Molecular distance edge between
all secondary carbons
2D MDE Desc
piPC1 Conventional bond order ID
number of order 1 (ln(1 + x)
2D Path Coun
TpiPC Total conventional bond order (up
to order 10) (ln(1 + x))
2D Path Coun
RDF60u Radial distribution function – 060/
unweighted
3D RDFDescr
Ku K global shape index/unweighted 3D PaDEL WH
L3m 3rd component size directional
WHIM index/weighted by relative
mass
3D PaDEL WHcomposition had the least effect for the group in the model
with MF value of 5.058.
Y-randomization test was employed to examine the robust-
ness of the model [35]. Y-randomization test afﬁrms whether
the model is acquired by chance correlation, as well as by val-
idating the sufﬁciency of the training set molecules. Y-
randomization test compares the stemmed scores with the
scores of the original QSAR model generated with non-
randomized data. On the off chance that the activity prediction
of the random model is practically identical to that of the orig-
inal model, then the set of observations is not sufﬁcient to sup-
port the model. The new QSAR models (after several
repetitions) were reported to have low R2 and Q2LOO values
for MOLT-4 and P388 cytotoxicity (Tables 3.1 and 3.2). In
the event that the opposite happens, then an adequate QSAR
model can’t be obtained for that particular modeling system
and information. The after effects of Table 3 show that an ade-
quate model is obtained by GA–MLR system, and the model
created is measurably noteworthy and vigorous. In Table 4,
statistical parameters such the mean square error (MSE) and
root mean square error (RMSE) for training and test set were
recorded to investigate the overall error included in the model.
The slope of the models and their coefﬁcients are also pre-
sented (Table 4), which validate the model strength and sup-
port other results presented in Tables 2 and 3.multiple regression model of MOLT-4.
e bsj MF P-value
(Conﬁdence Interval)
descriptor 2.306837 5.05878 0.991209
tion 1.483137 1.30994 0.401608
tion 0.15666 0.527872 6.4E05
d descriptor 0.25798 0.363175 6.11E05
tate indices 0.35577 0.136196 0.002068
electro-topological state 0.22154 0.638155 0.001632
electro-topological state 0.24298 1.058674 0.04033
electro-topological state 0.242366 0.46489 4.21E06
iphatic Chain Descriptor 0.239448 0.24072 0.000128
riptor 0.371 0.513501 0.005058
t Descriptor 3.00163 11.47603 6.38E07
t Descriptor 2.313908 7.83767 0.030934
iptor 0.68003 0.720658 0.031667
IMDescriptor 0.25853 0.820178 0.143251
IMDescriptor 0.25123 0.34245 0.991209
Table 2.2 Speciﬁcation of entered descriptors in genetic algorithm multiple regression model of P388.
Descriptors Deﬁnition Descriptor
Type
bsj MF P-value
(Conﬁdence Interval)
nAmide (Fragment Counts) Number of Amide groups Functional group
count
0.116478 0.010149 0.010108
nMethanal (Fragment Counts) Number of Methanal groups Functional group
count
0.45 0.02295 2.16E13
S_aaN Sum of aaN E-states Atom-type E-state
indices
0.432967 0.080783 8.3E13
AATSC4v Average centered Broto-
Moreau autocorrelation –
lag 4/weighted by van der
Waals volumes
2D Autocorrelation
Descriptor
0.170253 0.174265 0.000341
SpMax7_Bhm Largest absolute eigenvalue
of Burden modiﬁed matrix -
n 7/ weighted by relative
mass
2D Burden Modiﬁed
Eigenvalues
Descriptor
1.132729 1.105233 1.48E22
AVP-6 Average valence path, order
6
2D PaDEL Chi Path
Descriptor
0.187284 0.055003 0.000108
maxHdsCH Maximum atom-type H E-
State:=CH-
2D
Electrotopological
State Atom Type
Descriptor
0.482981 0.115616 3.29E13
TDB8e 3D topological distance
based autocorrelation – lag
8/weighted by Sanderson
electronegativities
Autocorrelation
3DDescriptor
0.64878 0.49436 3.13E14
RDF150u Radial distribution function
– 150/unweighted
3D RDFDescriptor 0.645457 0.098605 7.13E05
RDF140v Radial distribution function
– 140/weighted by relative
van der Waals volumes
3D RDFDescriptor 0.80804 0.12235 1.03E06
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By deciphering the descriptors contained in the model (Tables
2.1 and 2.2), it is conceivable to increase helpful chemical
insights into the activities of the anticancer compounds on
MOLT4 and P388 leukemia cell lines respectively. Hence, an
adequate translation of the QSAR results is given below.
nAtomic composition is a 1D descriptor that gives the total
number of atoms present in a given compound, its mean effect
in Table 2.1 for the MOLT4 model, was found to inversely
affect the activities derived with the model, large bsj values
strongly agrees with the mean effect (MF) and by decreasing
the contribution of this descriptor in novel compounds during
design efﬁciently promotes the chances of getting a more active
drug.
nAmide and nMethanal are fragment group count molecu-
lar descriptors which give the total sum of amide group and
formaldehyde group present in a wide range of the compounds
used in developing the model for cytotoxicity of P388 cell line,
and their mean effect presented in Table 2.2 shows that a
decrease in the number of methanal group and an increase in
the amide functional group improve the activity of an anti-
cancer compound on p388 cell line. The functional group
count and the fragment count can be derived from recognized
substructures within the molecule, i.e. they are 1D-descriptors;
in fact, they are also considered speciﬁc and substructure
descriptors. Count descriptors give local chemical informationthat is insensitive to isomer, conformational changes and show
a high level of degeneracy.
RDF60u, RDF150u and RDF140v are RDF descriptors
(Radial Distribution Function descriptors), and these descrip-
tors are based on the distance distribution in the geometrical
representation of a molecule and constitute a radial distribu-
tion function code (RDF code) that shows certain character-
istics in common with the 3D-MORSE code. RDF60u and
RDF150u were used in developing the models for predicting
the cytotoxicity of the compounds on MOLT-4 and P388
leukemia cell lines respectively, and this descriptor elucidates
the importance of unweighted radial function of the com-
pounds and weight radial function by relative van der Waals
volume for RDF140v descriptor which was used in the P388
model. These atomic properties discriminate the atoms of a
molecule for almost any property that can be attributed to
an atom. The radial distribution function in this form meets
all the requirements for a 3D descriptor, and it also provides
further valuable information such as bond distances, ring
types, planar and non-planar systems. This fact is a most
valuable consideration for a computer-assisted code
elucidation [40].
Ku and L3 m are WHIM descriptors (Weighted Holistic
Invariant Molecular descriptors) used in predicting the cytotox-
icity of a drug as stressed by some researchers [41,42], and their
relevance cannot be overemphasized. WHIM descriptors are
molecular descriptors based on statistical indices calculated
Table 3.1 R2Train and Q
2
LOO values after several Y-randomization tests for MOLT-4 cell line.
Iteration R R2 Q2
Random 1 0.405027 0.164046 0.30243
Random 2 0.297711 0.088632 0.30622
Random 3 0.390752 0.152687 0.14308
Random 4 0.485962 0.236159 0.06753
Random 5 0.375276 0.140832 0.25559
Random 6 0.386604 0.149463 0.33045
Random 7 0.398365 0.158695 0.22082
Random 8 0.334276 0.111741 0.34982
Random 9 0.461701 0.213168 0.12536
Random 10 0.383814 0.147314 0.29688
Random model parameters
Average r: 0.387258
Average r2: 0.1532
Average Q2: 0.23279
cRp2: 0.709688
The rm2 value for the dataset is: 0.920322.
The reverse rm2 value for the dataset is: 0.845831.
The average rm2 value for the dataset is: 0.883077.
The delta rm2 value for the dataset is: 0.074490.
For an acceptable QSAR model, the value of ‘‘Average rm2” should be >0.5 and ‘‘Delta rm2” should be <0.2.
Table 3.2 R2Train and Q
2
LOO values after several Y-randomization tests for P388 cell line.
Iteration R R^2 Q^2
Random 1 0.279538 0.078142 0.46107
Random 2 0.44716 0.199952 0.03866
Random 3 0.313826 0.098487 0.33728
Random 4 0.483343 0.23362 0.07857
Random 5 0.356249 0.126914 0.12739
Random 6 0.404394 0.163535 0.32245
Random 7 0.323082 0.104382 0.36066
Random 8 0.298103 0.088865 0.32915
Random 9 0.205889 0.04239 0.47215
Random 10 0.373691 0.139645 0.21416
Random model parameters
Average r: 0.359307
Average r2: 0.135609
Average Q2: 0.26735
cRp2: 0.825411
The value for the SCALED dataset is:
The rm2 value for the dataset is: 0.904361.
The reverse rm2 value for the dataset is: 0.820836.
The average rm2 value for the dataset is: 0.862599.
The delta rm2 value for the dataset is: 0.083525.
Each entry of submitted dataset is scaled as follows:
Scaled Z ðObserved or PredictedÞ ¼ ½Zminimum of Observed=½maximum of observedminimum of Observed
For an acceptable QSAR model, the value of ‘‘Average rm2” should be >0.5 and ‘‘Delta rm2” should be <0.2.
834 D.E. Arthur et al.on the projections of the atoms along principal axes. L3 m is
deﬁned as 3rd component size directional WHIM index/
weighted by relative mass, while Ku is K global shape index/
unweighted, and they are both 3D descriptors employed in
the MOLT-4 model to improve the probability for efﬁcient
prediction of anti-leukemia compounds speciﬁcally active on
MOLT-4 cell lines. These 3D descriptors improve the activity
of the model by signiﬁcantly improving the role of indepen-
dently measured directions and hence allowing simpler predic-
tive models to be developed.piPC1 and TpiPC are both 2D descriptors; piPC1 is deﬁned
as Conventional bond order ID number of order 1 (ln(1 + x),
it is a molecular multiple path count of order 01, while TpiPC
is the Total conventional bond order of the molecules used in
the MOLT4 model, and the mean effect of piPC1 was found to
positively inﬂuence the activity of the compounds when
increased, whereas TpiPC descriptor negates this effect if the
total conventional bond order is increased.
ATSC8v is a 2D auto correlation molecular descriptor
which is known as centered:centred Broto-Moreau
Table 4 Model performance parameters.
Parameters Formula pGI50 (P388)
Model
pGI50 (MOLT-4)
Model
R2 1
Pn
i¼1ðytry^trÞ
2Pn
i¼1ðytrytrÞ
2
0.9041 0.9702
adj R2 1
Pn
i¼1ðytry^trÞ
2=nm1Pn
i¼1ðytrytrÞ
2=n1 0.8875 0.9045
R2cv ¼ Q2 The average coeﬃcient of determination for the curve of predicted activity
versus experimental activity for test sets used for cross validation
0.8563 0.8812
R2m r
2 1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðr2  r20Þ
q 
0.5997 0.5080
MSEtr
Pn
i¼1ðytry^trÞ
2
n 0.1787 0.1733
RMSEtr
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPn
i¼1ðytry^trÞ
2
n
r
0.4228 0.4163
PRESStr
Pn
i¼1ðytr  y^trÞ2 17.677 29.583
r2r2o
r2
r2 is the coeﬃcient of determination for the curve of predicted activity
versus experimental activity for external validation (test set) and passing
through the origin it is r2o
0.0164 0.0626
r2r02o
r2
r’2o is the coeﬃcient of determination for the curve of experimental activity
versus against predicted activity for external validation (test set) passing
through the origin
0.0955 0.0567
k Slope of predicted activity versus experimental activity for external
validation (test set) passing through the origin
1.0280 1.051
k0 Slope of experimental activity versus against predicted activity for external
validation (test set) passing through the origin
0.9491 0.926
MSEtest
Pn
i¼1ðyexty^extÞ
2
z
1.0399 1.3444
R2pred 1
Ptext
i¼1 ðyexty^extÞ
2Ptext
i¼1 ðyextytrÞ
2 0.6701 0.6351
n is the number of molecule in the training set, m is the number of descriptors in the model, z is the number of molecule in the test or evaluation
set.
ytr is the experimental activity value for the training set, y^tr is the predicted activity value for the training set and ytr is the average or mean of the
experimental activity value for the training set.
yext is the experimental activity value for the test or evaluation set, y^ext is the predicted activity value for the test or evaluation set.
QSAR study of some compounds against MOLT-4 and P388 leukemia cell lines 835autocorrelation – lag 8, weighted by van der Waals volumes.
This descriptor was one of many included in the MOLT4
model, and it was used in the research paper titled ‘‘2D-
autocorrelation descriptors for predicting cytotoxicity of naph-
thoquinone ester derivatives against oral human epidermoid
carcinoma” [43], its mean effect negatively affects the activities
of the compounds used in the model, while the descriptor
minHBint10 and MaxHdsCH presented in Tables 2.1 and
2.2 above are 2D electropological state atom type descriptor
also used in developing MOLT4 and P388 model respectively,
and both chemical descriptors were found to positively inﬂu-
ence the activities of anticancer compounds on the cell lines.
Conclusions
The pGI50 for the leukemia cell lines P388 and MOLT-4 was
successfully modeled for a series of anticancer compounds col-
lected from NCI library. Genetic Functional Algorithm was
used to select highly correlated descriptors calculated with
paDEL software. The statistical parameters for the models sat-
isfy the criteria proposed by Tropsha, Roy and Grammaticafor validating QSAR models. A few descriptors such as piPC1,
nAtomic Composition and SpMax7_Bhm with mean effects of
11.48, 5.06 and 1.10 respectively, were found to be signiﬁ-
cantly responsible for the activities of the compound used in
the dataset.Conflict of Interest
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